Loading
Life sciences · Review
Frontiers in Medicine · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose This systematic review and meta-analysis aimed to compare the efficacy and safety of antibody-drug conjugates (ADCs) vs. conventional chemotherapy in patients with triple-negative breast cancer (TNBC) and to provide evidence for clinical decision-making and guideline development. Methods We systematically searched PubMed, Embase, and Cochrane Library and extracted data including hazard ratio (HR) and 95% confidence interval (CI) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for safety, and objective response rate (ORR). Results This study ultimately included 6 articles (5 dedicated RCTs for TNBC and 1 exploratory analysis of an HR-negative/HER2-low subgroup from the DESTINY-Breast04 trial), including 2,479 patients (1,256 patients in ADCs treatment and 1,223 patients in conventional chemotherapy). HR for PFS was 0.48 [95% CI (0.38, 0.61), P = 0.001], and HR for OS was 0.60 [95% CI (0.46, 0.79), P = 0.027]. OR for incidence of all adverse events (AEs) was 1.05 [95% CI (0.86,1.29), P = 0.901], and OR for incidence of grade ≥ 3 AEs was 1.11 [95% CI (0.88, 1.42), P = 0.984]. The pooled results demonstrated that ADCs significantly improved OS and PFS, while showing no significant increase in overall AEs or grade ≥ 3 AEs compared to control. Conclusion This study suggests that ADCs significantly improve OS and PFS without significantly increasing grade ≥ 3 AEs compared to conventional chemotherapy in TNBC, providing support for clinical decision-making and guideline development. These findings may inform future head-to-head trials, optimization of ADC-based combination regimens, and biomarker-guided precision treatment. As clinical data on novel ADCs continue to accumulate, these conclusions may be further validated and extended.